Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US Distributor Demands Better Biosimilars Support

Executive Summary

Removing legal hurdles and putting biosimilars on preferred formulary tiers will increase access and cut the cost of biologic therapies in the US, argues the chief of major healthcare distributor AmerisourceBergen.

You may also be interested in...

Dr Reddy’s De Vré On Momentum In US Biosimilars Market, Interchangeability

The global head of Dr Reddy’s biologics business unit, Raymond De Vré, discusses in an interview with Scrip how things are looking up in the US biosimilars market, why interchangeability isn’t a major concern and how galloping volume growth is being seen by the company in emerging markets.

Do Not Throw In Towel On Biosimilars, Says New Sandoz Chief

Assertions that the US should give up on supporting biosimilars in favor of controlling prices of off-patent biologic brands fail to recognize promising signs of progress, argues Richard Saynor, who has just taken over as CEO of biosimilars pioneer Sandoz.

US Insurer United Rewards Amgen’s Early Entry With Bevacizumab And Trastuzumab

Amgen’s Mvasi and Kanjinti alternatives to Roche’s Avastin bevacizumab and Herceptin trastuzumab brands will from 1 October be preferred by plans administered by the largest US health insurer, UnitedHealthcare.

Related Content


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts